Nancy Andrews - Novartis Non-Executive Independent Director
| NVS Stock | USD 113.21 1.65 1.48% |
Director
Dr. Nancy C. Andrews, M.D., Ph.D., was NonExecutive Independent Director of Novartis Inc. since February 27, 2015. She is a Member of the Research Development Committee and the Risk Committee. Dr. Andrews is dean emerita of the Duke University School of Medicine and vice chancellor emerita for academic affairs at Duke University in the United States. She served as dean and vice chancellor from 2007 to 2017. She is a professor of pediatrics, pharmacology and cancer biology at Duke, and was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She is chair of the board of directors of the American Academy of Arts and Sciences and of the Burroughs Wellcome Fund, a member of the Massachusetts Institute of Technology Corporationrationration, and former president of the American Society for Clinical Investigation. Additionally, she serves on the council of the National Academy of Medicine and on the Scientific Management Review Board of the US National Institutes of Health since 2015.
| Age | 63 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | Lichtstrasse 35, Basel, Switzerland, 4056 |
| Phone | 41 61 324 11 11 |
| Web | https://www.novartis.com |
Nancy Andrews Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nancy Andrews against Novartis stock is an integral part of due diligence when investing in Novartis. Nancy Andrews insider activity provides valuable insight into whether Novartis is net buyers or sellers over its current business cycle. Note, Novartis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Novartis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nancy Andrews over a month ago Acquisition by Nancy Andrews of 559 shares of Charles River at 228.41 subject to Rule 16b-3 |
Novartis Management Efficiency
The company has Return on Asset of 0.1009 % which means that on every $100 spent on assets, it made $0.1009 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2628 %, implying that it generated $0.2628 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.13 in 2025. Return On Capital Employed is likely to drop to 0.14 in 2025. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.5 B in 2025, whereas Intangible Assets are likely to drop slightly above 22.7 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Katherine Baicker | Eli Lilly and | 49 | |
| Christine Seidman | Merck Company | 68 | |
| Marschall Runge | Eli Lilly and | 66 | |
| Karen Walker | Eli Lilly and | 59 | |
| Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Marillyn Hewson | Johnson Johnson | 67 | |
| James Smith | Pfizer Inc | 61 | |
| Mark Weinberger | Johnson Johnson | 59 | |
| Jackson Tai | Eli Lilly and | 71 | |
| Roxanne Austin | AbbVie Inc | 60 | |
| Ian Davis | Johnson Johnson | 70 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
| Frederick Waddell | AbbVie Inc | 67 | |
| Robert Bertolini | Bristol Myers Squibb | 58 | |
| Lynn Elsenhans | GlaxoSmithKline PLC ADR | 64 | |
| Carolyn Bertozzi | Eli Lilly and | 53 | |
| Inge Thulin | Merck Company | 67 | |
| Jesse Goodman | GlaxoSmithKline PLC ADR | 69 | |
| Thomas Cech | Merck Company | 72 | |
| Gabrielle Sulzberger | Eli Lilly and | 60 | |
Management Performance
Novartis AG ADR Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Sloan Simpson, Global Relations | ||
| Charlotte Wieser, Corporate Secretary | ||
| Joerg Reinhardt, Independent Non-Executive Chairman of the Board | ||
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Karen Hale, Chief Legal Officer, Member of the Executive Board | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| Etienne Jousseaume, Cell Access | ||
| Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | ||
| John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | ||
| Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Customer and Technology Solutions, Member of the Executive Committee | ||
| Patrick MD, President International | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Victor Bulto, President Innovative Medicines US, Member of the Executive Board | ||
| Fiona Marshall, President Research | ||
| Patrice Bula, Non-Executive Independent Director | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Linda MD, Global Development | ||
| Shreeram MD, President Officer | ||
| Andreas Planta, Non-Executive Independent Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Non-Executive Independent Director | ||
| Srikant Datar, Non-Executive Independent Director | ||
| MarieFrance Tschudin, President, Innovative Medicines International and Chief Commercial Officer, Member of the Executive Board | ||
| Robert Kowalski, Chief People and Organization Officer | ||
| Samir MD, Global Relations | ||
| Simon Moroney, Non-Executive Independent Director | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | ||
| Aharon Gal, Chief Officer | ||
| Vasant MD, Chief Officer | ||
| Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | ||
| Bridgette Heller, Non-Executive Independent Director |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 238.05 B | ||||
| Shares Outstanding | 1.98 B | ||||
| Shares Owned By Institutions | 6.76 % | ||||
| Number Of Shares Shorted | 5.04 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 5.00 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.